This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Rizzo, M A Articles by Vollmer, T L Search for Related Content PubMed PubMed Citation Articles by Rizzo, M A Articles by Vollmer, T L Social Bookmarking                         What's this?

Prevalence and treatment of spasticity reported by multiple sclerosis patients

Yale MS Clinic and Research Center, Yale University School of Medicine, 40 Temple, Suite 6c, New Haven, CT 06510, USA, Marco.Rizzo{at}Yale.edu

O C Hadjimichael

Yale MS Clinic and Research Center, Yale University School of Medicine, 40 Temple, Suite 6c, New Haven, CT 06510, USA

J Preiningerova

Yale MS Clinic and Research Center, Yale University School of Medicine, 40 Temple, Suite 6c, New Haven, CT 06510, USA

T L Vollmer

Barrow Neurological Institute, 350 West Thomas Road, Phoenix, AZ 85013, USA

The objective of this study was to characterize the population of multiple sclerosis (MS) patients suffering from spasticity and to evaluate treatment patterns, including intrathecal baclofen (ITB) delivery, related to patient quality of life (QOL). We conducted a cross-sectional, two-level study using data from the Patient Registry of the North American Research Committee on MS (NARCOMS). In addition, we surveyed a subgroup of 198 preselected patients who are using ITB (ITBG) and a random sample of 315 oral drug users (ORALG). Among the registrants, 16% reported no spasticity, 31% minimal, 19% mild, 17% moderate (frequently affects activities), 13% severe (daily forced to modify activities) and 4% total (prevents daily activities). Patients experiencing greater severity included by proportion males, and those older and with longer duration of MS. QOL scores decreased inversely with severity. In the focused survey, ITBG reported lower levels of spasticity than ORALG, less stiffness in the legs, less pain and fewer spasms at any time. They scored significantly lower in the SF-36 physical component, yet reported less fatigue on the MFIS scale. Prevalence data reveal that one third of MS patients modify or eliminate daily activities as a result of spasticity. Treatment of spasticity can significantly impact QOL parameters by reducing spasms, pain and fatigue.

Key Words: epidemiology • intrathecal baclofen • multiple sclerosis • prevalence • quality of life • spasticity • treatment

Multiple Sclerosis, Vol. 10, No. 5, 589-595 (2004)
DOI: 10.1191/1352458504ms1085oa


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				R.A. Marrie and M. Goldman Validity of performance scales for disability assessment in multiple sclerosis Multiple Sclerosis, November 1, 2007; 13(9): 1176 - 1182. [Abstract] [PDF]

				R. A. Marrie, G. Cutter, T. Tyry, T. Vollmer, and D. Campagnolo Disparities in the management of multiple sclerosis-related bladder symptoms Neurology, June 5, 2007; 68(23): 1971 - 1978. [Abstract] [Full Text] [PDF]

				D. Centonze, G. Koch, V. Versace, F. Mori, S. Rossi, L. Brusa, K. Grossi, F. Torelli, C. Prosperetti, A. Cervellino, et al. Repetitive transcranial magnetic stimulation of the motor cortex ameliorates spasticity in multiple sclerosis Neurology, March 27, 2007; 68(13): 1045 - 1050. [Abstract] [Full Text] [PDF]

				K Rasova, E Havrdova, P Brandejsky, M Zalisova, B Foubikova, and P Martinkova Comparison of the influence of different rehabilitation programmes on clinical, spirometric and spiroergometric parameters in patients with multiple sclerosis Multiple Sclerosis, April 1, 2006; 12(2): 227 - 234. [Abstract] [PDF]

				D B. smail, A Peskine, N Roche, L Mailhan, J B Thiebaut, and B Bussel Intrathecal baclofen for treatment of spasticity of multiple sclerosis patients Multiple Sclerosis, February 1, 2006; 12(1): 101 - 103. [Abstract] [PDF]